Lazard Asset Management »

Taysha Gene Therapies shares owned by Lazard Asset Management

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by Lazard Asset Management from 13F filings

Historical chart of Lazard Asset Management investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by Lazard Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by Lazard Asset Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $0 8.8k 0.00

More positions owned by Lazard Asset Management

Microsoft Corp Common Stock (MSFT)
Alphabet Inc A Common Stock (GOOGL)
Amazon.com Common Stock (AMZN)
Norfolk Souther Common Stock (NSC)
Visa Common Stock (V)
Accenture Common Stock (ACN)
Intercontinen Common Stock (ICE)
Unitedhealth Gr Common Stock (UNH)
Aon Plc/ireland Common Stock (AON)
Bank Of America Common Stock (BAC)
Thermo Fisher Common Stock (TMO)
Analog Devices Common Stock (ADI)
Mcdonalds Corp Common Stock (MCD)
John & John Common Stock (JNJ)
Amer Express Common Stock (AXP)

View all positions for Lazard Asset Management

Top funds holding Taysha Gene Therapies

RA Capital Management
VR Adviser
Vanguard Group
venBio Select Advisor
Baker Bros. Advisors
Artal Group
Millennium Management
Point72 Asset Management
Citadel Advisors
T. Rowe Price Associates
Schonfeld Strategic Advisors
Exome Asset Management
Alphabet
Quantum Private Wealth
Palo Alto Investors

View all funds holding Taysha Gene Therapies